Our pipeline


Izokibep is a unique antibody mimetic and potent interleukin-17A (IL-17A) inhibitor designed to overcome the limitations of existing monoclonal antibodies.


* FDA has previously granted orphan drug status for the treatment of these rare diseases.

More than 300 patients have been exposed to izokibep to date, many for up to three years. These data confirm the safety profile of izokibep that supports our strategy to evaluate IL-17A inhibition more fully in pursuit of transformative efficacy across many disease states.

About Izokibep

Izokibep also has a unique molecular design that differentiates it from other IL-17A inhibitors. It has a very high affinity (0.3 pM) and selectivity to IL-17A meaning it blocks IL-17A more completely and at markedly lower dose levels than approved monoclonal antibodies. In addition, the small molecular size of izokibep, about 1/10th the size of a monoclonal antibody, gives it the potential to reach targeted tissues that may otherwise be inaccessible to the much larger monoclonal antibodies. Finally, the addition of an albumin binding domain increases the plasma half-life and further enhances tissue penetration.


IL-17A is one of the best-studied cytokines in immunology, especially around its involvement in inflammatory pathology. IL17 has a major role in numerous inflammatory diseases and inhibiting IL-17A signaling has proven effective in treating a variety of diseases including plaque psoriasis, psoriatic arthritis, and ankylosing spondylitis. IL-17 plays a role in other rare diseases and conditions including non-infectious uveitis, an inflammation inside the eye, and hidradenitis suppurativa, a devastating, chronic inflammatory disease of the exocrine glands characterized by painful malodorous lumps under the skin that can become scarred and disfiguring.


With its unique properties, including extraordinary potency and small molecular size, izokibep can overcome the limitations of existing monoclonal antibodies and achieve high drug exposures and enhanced tissue penetration. In addition, because of the extremely high potency and much reduced molecular size, izokibep can reach high drug exposure levels through a single subcutaneous injection that monoclonal antibodies require intravenous (IV) administration to achieve. Therefore, izokibep has the potential to offer meaningfully differentiated efficacy in a host of IL-17 autoimmune diseases positively impacting the lives of patients around the world.

Izokibep is not yet approved for use in any indication.